Tenax Therapeutics Expands Phase 3 LEVEL Program
The Phase 3 LEVEL Study is set to grow, boosting statistical power and preparing for a second global registrational study.
Tenax Therapeutics, Inc. (Nasdaq: TENX), a company committed to enhancing cardiopulmonary therapies, has announced significant advancements in its Phase 3 LEVEL program. This initiative focuses on TNX-103 (oral levosimendan), aimed at treating pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF). The U.S. Food and Drug Administration (FDA) has accepted an updated development plan that will allow the company to enlarge the LEVEL study. This expansion will increase patient enrollment from 152 to at least 230, thereby elevating the statistical power of the study to over 95%. The first group of patients is anticipated to be enrolled by the end of 2025.
Additionally, in a promising step forward, the FDA has agreed to initiate a second global Phase 3 study named LEVEL-2, with the enrollment of the first patient expected to happen this year. This dual approach not only enhances the research capabilities of Tenax, but also presents new opportunities for patients suffering from PH-HFpEF, a condition that currently has no approved treatment options.
Elevating Clinical Development for TNX-103
The commitment of Tenax Therapeutics towards advancing clinical development for TNX-103 is evident. Chris Giordano, the President and CEO, emphasized that the company's recent $100 million financing provides the necessary momentum to chase this ambitious goal. With over 50 North American sites activated, the enrollment process for the expanded LEVEL study is progressing favorably, and there is optimism about completing enrollment on schedule.
The LEVEL study has already shown promising results, with preliminary data indicating that TNX-103 is well-tolerated among patients. An impressive 95% of patients who were randomized remain on therapy, suggesting strong adherence and positive patient experiences. The involvement in the ongoing extension phase (OLE) has also demonstrated encouraging results, with over 95% of patients choosing to continue their participation after the initial 12 weeks of treatment.
Insights from Clinical Trials
Dr. Stuart Rich, the Chief Medical Officer at Tenax, shared insights reflecting the robust adherence to the study's requirements. Continuation rates for therapy and participation are high, indicating the potential of TNX-103 to provide meaningful benefits for patients. Notably, a substantial portion of participants in the OLE have been engaged for over six months, with some for more than a year, allowing researchers to gather critical long-term data.
What to Expect from LEVEL-2
The LEVEL-2 study is designed to be a global, double-blind, randomized, placebo-controlled trial that will further examine the efficacy of TNX-103. Tenax aims to enroll a greater number of patients than the LEVEL study, with an emphasis on gathering comprehensive data over a year of treatment. The primary endpoint will focus on assessing the six-minute walk distance (6MWD) at 26 weeks, providing essential data on the drug's effectiveness.
Tenax Therapeutics believes that TNX-103 has the capacity to significantly enhance the quality of life for patients afflicted with this challenging condition. Dr. Rich expressed optimism that with successful outcomes in Phase 3 trials, patients with PH-HFpEF may soon have access to an approved treatment.
Understanding Levosimendan
Levosimendan is unique in its class as a potassium ATP channel activator and calcium sensitizer. This drug impacts the heart and vascular system through a range of mechanisms that are crucial for treating PH-HFpEF. Initially developed by Orion Corporation in Finland, intravenous levosimendan is already authorized for use in multiple countries, demonstrating its established efficacy in acute heart failure situations. The results from earlier studies indicate that intravenous levosimendan has shown beneficial outcomes, including improved exercise capacity for patients suffering from heart failure.
About Tenax Therapeutics
Founded with a vision to create innovative cardiopulmonary therapies, Tenax Therapeutics, Inc. continues to lead the charge in advancing treatments for underserved patient populations. The company holds global rights to levosimendan and prioritizes bringing this medication to market. Alongside its commitment to TNX-103, Tenax is also exploring further development opportunities, including oral formulations of other critical medications. For more information, you can visit their official site.
Frequently Asked Questions
What is the purpose of the Phase 3 LEVEL program?
The program aims to evaluate the effectiveness and safety of TNX-103 in treating patients with PH-HFpEF.
How many patients will be involved in the LEVEL study?
The LEVEL study plans to enroll at least 230 patients to enhance the statistical power of the outcomes.
When is the anticipated start for the LEVEL-2 study?
The LEVEL-2 study is expected to initiate patient enrollment this year.
What positive outcomes have been observed in the ongoing clinical trials?
Early results indicate high adherence rates, with over 95% of participants remaining on therapy and choosing to continue in OLE.
What is the significance of levosimendan in treating PH-HFpEF?
Levosimendan has shown potential as a treatment for PH-HFpEF, addressing critical unmet needs for patients facing this serious condition.
